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Abstract
Isolation of polyadenilated mRNA from human immortalized bronchial epithelial cell line BEP2D revealed the presence of
multiple isoforms of RNA coded by the CHRNA9 gene for a9 nicotinic acetylcholine receptor (nAChR). BEP2D cells were
homozygous for the rs10009228 polymorphism encoding for N442S amino acid substitution, and also contained mRNA
coding for several truncated isoforms of a9 protein. To elucidate the biologic significance of the naturally occurring variants
of a9 nAChR, we compared the biologic effects of overexpression of full-length a9 N442 and S442 proteins, and the
truncated a9 variant occurring due to a loss of the exon 4 sequence that causes frame shift and early termination of the
translation. These as well as control vector were overexpressed in the BEP2D cells that were used in the assays of
proliferation rate, spontaneous vs. tobacco nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced
cellular transformation, and tumorigenicity in cell culture and mice. Overexpression of the S442 variant significantly
increased cellular proliferation, and spontaneous and NNK-induced transformation. The N442 variant significantly decreased
cellular transformation, without affecting proliferation rate. Overexpression of the truncated a9 significantly decreased
proliferation and suppressed cellular transformation. These results suggested that a9 nAChR plays important roles in
regulation of bronchial cell growth by endogenous acetylcholine and exogenous nicotine, and susceptibility to NNK-
induced carcinogenic transformation. The biologic activities of a9 nAChR may be regulated at the splicing level, and genetic
polymorphisms in CHRNA9 affecting protein levels, amino acid sequence and RNA splicing may influence the risk for lung
cancer.
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Introduction
The functional components of cholinergic system are highly
conserved among the invertebrate and vertebrate species. Previous
genome wide association studies revealed single nucleotide poly-
morphisms (SNPs) in the CHRNA5-CHRNA3-CHRNB4 gene
cluster on chromosome 15 that encodes the a5, a3a n db4 subunits
of the nicotinic acetylcholine receptors (nAChRs) associated with
nicotine dependence and lung cancer [1,2,3]. However, the majority
of these SNPs do not affect protein sequences, because they are
located in non-coding regions or result in synonimous codon
substitutions. The genetic variations in other nAChR subunits
expressed in lung epithelia [4,5,6,7] remain largely unknown.
In the past, we have established an important role for nAChRs
expressed on respiratory cells in the malignant transformation
caused by pharmacological doses of tobacco-derived carcinogenic
nitrosamines, and demonstrated that nicotinic antagonists can
abolish these pathobiologic effects [8]. Nicotine and its carcino-
genic derivatives can contribute to the development of lung cancer
by acting as tumor promoters that facilitate the outgrowth of cells
with genetic damage [9]. In contrast, inhibition of nAChRs
induces apoptosis of lung cancer cells and produces anti-
carcinogenic effects [10,11,12]. Therefore, pulmonary nAChRs
are now widely considered as novel drug targets for prevention
and treatment of lung cancer [13,14,15].
We focused this study on the CHRNA9 gene encoding a9
nAChR originally cloned by us from human epidermal keratino-
cytes [16]. Recent publications have demonstrated overexpression
and activation of the a9 nAChR in human breast epithelial cells
during tumorigenesis [17], and antitumor effects of inhibition of
a9 signaling in human breast cancer cells [18,19].
In this study, we evaluated effects of the naturally occurring
variants of a9 nAChR in the cellular proliferation and neoplastic
transformation. The results demonstrated dramatic variations in
the biologic effects of a9 variants on human bronchial cells. These
findings suggest a role of a9 nAChR in lung cancer development
and progression.
Methods
Ethic Statement
All animal work have been conducted according to relevant
national and international guidelines. The protocol of animal
experiments number 2007–2732 was approved by the Univer-
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Committee.
Expression of CHRNA9 variants
The BEP2D cell line was a kind gift from Dr. Harris (NCI,
NIH). This human papillomavirus-immortalized human bronchial
epithelial cell line is non-tumorigenic, anchorage-dependent and
sensitive to contact growth inhibition [20]. The cells were grown in
EpiLifeH medium containing 60 mM calcium and Human Corneal
Growth Supplement (Invitrogen, Carlsbad, CA) in a humidified
incubator at 5% CO2 and 37uC. Total RNA was purified from
BEP2D cells using RNA purification kit (Qiagen, Valencia, CA).
The SuperScript III First-Strand Synthesis SuperMix (Invitrogen)
was used for cDNA synthesis with oligo(dT) primer. cDNA was
amplified using the Platinum PCR SuperMix High Fidelity
(Invitrogen), and the primers 59 GATGAACTGGTCCCATT-
CCTG and 59 GATAGCAAAGCCAATATCTGTG. The oligo-
nucleotides 59GAATGCTGCGGCCGCATGAACTGGTCCCA-
TTCCTGCATC and 59CTCTGCTACGCGTAGCCAATATC-
TGTGACTAATCC were used for the second round of PCR and
preparation of the cDNA fragment for cloning. The CHRNA9
open reading frame was inserted into pLVX-tight-Puro plasmid
(Clontech, Mountain View, CA)by NotI/MluI restriction sites. The
N442 variant of the protein was prepared by site-directed
mutagenesis with the use of QuikChange II XL Site-Directed
Mutagenesis Kit (Agilent Technologies, Inc. Santa Clara, CA) and
oligonucleotides 59GACCACAAGGCCACCAATTCCAAGGG-
GAGTG and 59CACTCCCCTTGGAATTGGTGGCCTTGT-
GGTC. Lentiviral particles containingCHRNA9 expressing pLVX
vectors and non-expressing control vector were mixed with pLVX-
Tet-offlentivirusandused fortransductionofBEP2Dcellsfollowing
the manufacturer’s protocol. Recombinant cells were selected and
maintained in presence of 50 mg/ml of Geneticine (G418) and
5 ng/ml of Puromycin (Invitrogen). Antibiotic-resistant cells were
maintained for less than 4 passages prior to experiments.
Quantitative real-time PCR (qPCR)
RNA was purified from the exponentially growing cells and
treated by RNase-Free DNase (Qiagen), followed by preparation
of cDNA, as described above. Platinum SYBR Green qPCR
Super Mix-UDG with ROX (Invitrogen) was used for qPCR with
100 mg of cDNA and the following primers: the full-length mRNA
specific primers 59CTTATATAACAAGGCTGATGATG and 59
CAAAAGTCAGGTTGCACTG; the 122 amino acid (aa) variant
specific primers 59 CATCGTCTTATATAACAAGTAAATAC
and 59GGTTAGACTCTGGGAGTTTG; and the primers com-
mon for both variants of CHRNA9 cDNA 59CTCTCTCAGA-
TTAAGGATATGG and 59 CTAGGCCATCGTACTGATC.
The following primers specific for human ubiquitin C gene were
used as loading control: 5’GAACGCCGATGATTATATAAG
and 59CATTGTCAAGTGACGATCAC. Quality of each reac-
tion was controlled by dissociation curves and 2% agarose gel
electrophoresis. Results of all qPCR reactions, performed with use
of 7500 Real-Time PCR System (Applied Biosystems, Carlsbad,
Ca), were adjusted by corresponding loading control data.
Standard curve including multiple dilutions of the positive control
plasmid was used to convert Ct-values into fold-difference for each
pair of primers. One-way ANOVA with the Bonferroni post-test
was used for statistical analysis.
Cell growth and transformation assays
Exponentially growing BEP2D cells were plated on multiple
60 mm dishes at a density of 5610
4 cells per dish. The cells were
counted in replica plates every 48 h using Cellometer Auto T4
(Nexcelom, Lawrence, MA), and the results of 4 independent
experiments were analyzed. To determine susceptibility to
carcinogenic transformation, BEP2D cells were exposed to 2 mg/
ml of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK; To-
ronto Research Chemicals Inc., Canada) or to mock for 48 h, put
through 5 subsequent passages, and used in the soft agar
anchorage-independent growth assay [8,21,22] and focus-forma-
tion assay [21,22]. All experiments were performed in antibiotic-
free media. In the anchorage-independent growth assay, multiple
dilutions of test BEP2D cell lines in the media containing 0.3% of
agar placed on the solidified layer of 0.5% agar were incubated for
14 days, stained with 0.01% crystal violet in 70% methanol, and
the colonies containing at least 50 cells were counted with the aid
of dissection microscope. In the focus-formation assay, the cells
were grown in T-25 flasks for 14 days with changing medium
every 3 days, washed and stained by 0.05% crystal violet in 80%
methanol. The foci were counted in three 1 cm
2 randomly
selected fields in each flask.
Tumorigenesis assay
The cells were treated by NNK and seeded into soft agar, as
described above. Colonies grown for 2 weeks in soft agar were
randomly selected, picked with the aid of the dissection
microscope and plated in a regular growth medium. Cell colonies
were cultivated for two passages and the transformed clones were
propagated in the RPMI medium (Invitrogen) containing 10% of
heat-inactivated FBS and Antibiotic-Antimycotic (Invitrogen).
Anchorage-independent colonies are resistant to FBS-induced
terminal transformation [23]. Approximately 2610
7 cells from
each colony were injected subcutaneously to 4 weeks old male
SCID mice (NOD.Cg-Prkdc
scid Il2rg
tm1Wjl/SzJ, The Jackson
Laboratory, Sacramento, CA). Each mouse received 4 different
cell clones, one per each of the bilateral front and rear trunkal
locations. Mice were monitored weekly for the appearance of
tumors and euthanized 2 months post-injection, and visible tumors
were harvested and examined microscopically. These experiments
were performed blindly with regard to the type of injected BEP2D
cell clones.
Statistical analysis
All statistical analyses were performed using the ‘‘Prism’’
software (GraphPad Software Ink., La Jolla, CA). One-way
ANOVA with the Bonferroni post-test was used for analysis of
allele-specific qPCR data. Two-tailed paired t-test was used for
analysis of cellular proliferation, and two-tailed non-parametric
test was used for analysis of cellular transformation. Two-tailed
Fisher’s exact test was used in the tumorigenesis assay. In all
experiments, differences were deemed significant if the p value
calculated with 95% confidence interval was less than 0.05.
Results
Naturally occurring variants of a9 nAChR expressed in
BEP2D cells
Polyadenilated CHRNA9 mRNA was cloned from BEP2D cells
into pLVX vector. Sequence of resulting plasmids revealed
presence of four isoforms of a9 mRNA (Fig. 1). The BEP2D
cell line was found to be homozygous for the rs10009228
polymorphism and express an a9 nAChR protein with the
N442S aa substitution. In addition to the normally spliced
CHRNA9 mRNA, one of the isoforms had remaining intron 1
and another one had intron 2 sequences. These two isoforms may
lead to frame-shifts and manifestation of the termination codon
after aa 41 and 75, respectively. They were previously found in
Variants of Human a9 Nicotinic Receptor
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NCBI database (http://www.ncbi.nlm.nih.gov/IEB/Research/
Acembly/av.cgi?exdb=AceView&db=36a&term=CHRNA9).
The newly discovered fourth mRNA isoform resulted from the
compete loss of the exon 4. This RNA splicing translates into the
truncated 122 aa peptide that includes the 25 aa signal peptide and
a part of the predicted neurotransmitter gated ion-channel ligand
binding domain, but not the predicted transmembrane domain
(Fig. 2).
Overexpression of a9 nAChR variants in BEP2D cells
The biologic significance of a9 variants was evaluated in
BEP2D cells overexpressing the reference sequence of a9
containing N442 aa (NP_060051; prepared by the site-directed
mutagenesis), the a9 containing S442 aa substitution (rs10009228;
expressed in intact BEP2D cells) and the truncated 122 aa a9
peptide vs. the non-expressing vector pLVX (negative control).
The resultant BEP2D cell lines were named by the a9 nAChR
variant they overexpressed, i.e., "N442," "S442," ‘‘truncated’’ and
Figure 1. Structure and splicing of human CHRNA9 gene. A. Structure of the human CHRNA9 gene. Exons are shown as rectangles and introns
are shown as lines. B, C, D, E. Variants of the splicing of mRNA coded by the CHRNA9 gene detected in BEP2D cells. The mRNAs for full-length (B)
and truncated proteins (C, D, E) expressed in BEP2D cells. The truncated a9 used in overexpression experiments resulted from a loss of the exon 4
that causes frame shift with 122 aa peptide translation (C).
doi:10.1371/journal.pone.0027978.g001
Figure 2. Alignment of a9 nAChRs from various mammals. Predicted functional domains are depicted by arrows. Alignment and annotations
were generated using the Geneious software (Biomatters Ltd, Auckland, New Zealand). Protein sequences were obtained from the NCBI database.
Asterisk indicates end of the 122 aa peptide translation. The N442S aa substitution region is highlighted by the red frame. Due to the gap in the
alignment this aa appeared at position 443.
doi:10.1371/journal.pone.0027978.g002
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(p,0.05) overexpression in experimental BEP2D cells of all three
experimental a9 target mRNA, in comparison to the negative
control cells (Fig. 3).
Variants of a9 nAChR differentially influence proliferation
and neoplastic transformation of BEP2D cells
The S442 overexpressing BEP2D cells demonstrated significant
(p,0.05) increase in the proliferation rate, compared to other cell
lines (Fig. 4A). No difference between the growth rates of N442
and control cells was seen (p.0.05). In contrast, the BEP2D cells
expressing truncated variant of a9 had a significantly (p,0.05)
decreased growth rate.
The effect of a9 variants on spontaneous and NNK-induced
cellular transformation was tested in both anchorage-independent
growth (Fig. 4B) and focus formation (Fig. 4C) assays. Soft agar
assay measures the fraction of cells that gained ability to grow
without attachment to surface. Focus formation assay allows to
visualize cells that lost contact growth inhibition and started to
grow in multiple layers. Both assays brought similar results
demonstrating dramatic differences among tested BEP2D cell
lines. Overexpression of S442 a9 led to a significant (p,0.05)
increase in both spontaneous and NNK-induced cellular transfor-
mation. In marked contrast, the N442 a9 variant significantly
(p,0.05) reduced both spontaneous and NNK-induced transfor-
mation, compared to the control cells containing an empty vector.
Overexpression of truncated a9 variant also led to a significant
(p,0.05) decrease in both spontaneous and NNK-induced cellular
transformation, compared to control. Notably, NNK-treatment
caused no significant increase in the transformation of BEP2D
cells overexpressing the 122 aa variant. These results demonstrat-
ed for the first time that overexpression of the truncated a9 variant
protects BEP2D cells from the carcinogenic transformation caused
by NNK.
In vivo tumorigenesis
To confirm that results of our in vitro assays indeed represented
tumorigenesis, we isolated single transformed BEP2D cell clones
from the soft agar for expansion and subsequent injection to SCID
mice. We isolated a total of 24 transformed colonies from each cell
line growing in soft agar, and cultivated them for two passages in
the EpiLifeH medium used for maintaining BEP2D cell lines.
Then, the cells were fed with RPMI medium containing 10% of
heat inactivated FBS and expanded through three additional
passages. It has been previously shown that anchorage-indepen-
dent colonies obtained from BEP2D cells are resistant to FBS-
induced terminal differentiation and survive this treatment [23].
Recovery of the transformed clones originated from N442, S442
and pLVX cell lines was at least 20 clones for each cell line, or
83%. In marked contrast, only 6 of 24 clones, or 25%, isolated
from the BEPD2D cell line overexpressing truncated a9 protein
were resistant to treatment with FBS. Such a low yield of viable
clones indicated that overexpression of truncated a9 dramatically
increases resistance to NNK-induced cellular transformation. To
avoid spurious results due to huge differences in cell survival
compared to other cell lines, the clones representing overexpres-
sion of truncated a9 variant were not used in in vivo experiments.
Transformed clones originated from N442, S442 and pLVX
cell lines were injected subcutaneously to SCID mice. The
morphological and histological analyses performed 2 months after
inoculation revealed differences among their tumorigenic poten-
tial. Fisher’s exact test demonstrated a significant (p,0.05)
increase in tumor formation by the S442 overexpressing BEP2D
cells (Table 1). This finding indicated that S442 variant of a9
nAChR not only elevates cellular transformation, but also
promotes tumorigenicity of transformed clones.
Discussion
In this study, we demonstrated for the first time that different
variants of human a9 nAChR subunit protein differentially
influence regulation of bronchial cell proliferation and suscepti-
bility to the tumorigenic transformation by NNK. Several normal
human polymorphisms affecting aa sequence of a9 nAChR are
reported in the NCBI database. Surprisingly, while the reference
sequence of a9 nAChR NP_060051 contains N442 aa, available
population data indicate that the reference allele has average
Figure 3. Overexpression of a9 nAChR variants in BEP2D cells. The relative amounts of mRNA encoding the variants of a9 nAChR
overexpressed in BEP2D cell lines were measured by qPCR, as detailed in Methods, using the primers common for all a9 isoforms (A), specific for the
full length a9( B), and specific for the 122 aa truncated a9 variant (C). Data are means 6 SEM of qPCR experiments performed with at least 3
biological replicates of each cell line and expressed as fold of pLVX control, taken as 1. One-way ANOVA with the Bonferroni post-test was used for
analysis of allele-specific qPCR data.
doi:10.1371/journal.pone.0027978.g003
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SNP encoding the S442 a9 variant is approximately 0.8 (http://
www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10009228).
Most importantly, our recent case-control study has demonstrated
a significant association of the N442 a9 nAChR variant with a
decreased risk of lung cancer [24].
Overexpression in BEP2D cells of the most frequent a9
population variant S442 promoted proliferation and facilitated
NNK-induced tumorigenesis. An overexpression and activation of
a9 in breast epithelial cells has been observed during tumorigen-
esis [17]. Further, inactivation of a9 signaling can inhibit
proliferative, angiogenic and metastatic effects of nicotine/
smoking [15,18,19]. The fact that S442 stimulated both cellular
proliferation and tumorigenic transformation, suggested that the
most common a9 nAChR variant acts as a tumor promoter. The
tumor promoting activity may result from an increase in the
proliferation rate and/or facilitation of genomic instability.
Suppression of cellular transformation by the N442 a9 variant
and relatively rare occurrence of this ancestral protein in human
population prompted further analysis. Based on the protein
sequence alignment of the CHRNA9 homologs expressed in
various mammalian species (Fig. 2), some parts of C-terminal
domain display a large level of variability, but the aa spanning the
428–462 region are conserved among various species. Interesting-
ly, while the majority of mammals carry the N442 variant, humans
most commonly feature the S442 variant. Noteworthy, previous
characterization of the ligand binding profile of a9 nAChR in
Xenopus oocytes, which revealed an unusual response to the
canonical agonists such as nicotine [25], was performed using
the rat a9 nAChR that contains N442 residue. Our results
demonstrating opposite effects of N442 and S442 variants on cell
growth and resistance to oncogenic transformation suggest that the
two variants may vary in their response to ligands, which needs to
be elucidated in a separate study.
The results of the present study also demonstrated for the first
time that overexpression of the truncated a9 variant increases
resistance of BEP2D cells to carcinogenic transformation caused
by NNK. Previously, we have reported that inhibition of
acetylcholine signaling in BEP2D cells significantly reduces
NNK-associated cellular transformation [8]. Therefore, it can be
postulated that function of CHRNA9 gene in the acetylcholine
signaling axis can be physiologically regulated at the level of RNA
splicing.
Various isoforms of CHRNA9 mRNA are detected in different
cell and tissue types (http://www.ncbi.nlm.nih.gov/IEB/Research/
Acembly/av.cgi?exdb=AceView&db=36a&term=CHRNA9).
Two CHRNA9 isoforms are expressed in cochlear hair cells of the
chick [26]. The epigenetic regulation of cholinergic function by
means of mRNA splicing has been characterized in the lower
species that possess a smaller number nAChR genes, compared to
humans. The posttranscriptional RNA modifications diversify the
nAChR in insects [27,28,29]. In lower species, the RNA splicing
may result in truncated nAChR proteins that can alter ligand
binding charetristics [30] and mediate resistance to toxins [31]. The
alternative splicing has been also reported for various mammalian
nAChR genes, and can be associated with human diseases. For
example, alternative splicing in the neuronal a4 and a7 nAChR
Figure 4. Differential effects of a9 nAChR variants on cell growth and neoplastic transformation. A. Growth curves. Total number of cells
per a 6-well plate for BEP2D cells overexpressing N442, S442 or truncated a9 and control cells infected with empty pLVX vector. The data are means
6 SEM obtained in 4 independent experiments. B, C. Cellular transformation assays. The BEP2D cells overexpressing N442, S442 or truncated a9 and
control cells infected with empty pLVX vector were incubated for 48 h without (spontaneous transformation) or with 2 mg/ml NNK (NNK-induced
transformation) and analyzed in soft agar (B) or focus formation (C) assay, as detailed in Methods. The data are means 6 SEM obtained in at least 3
independent experiments. Asterisks =p,0.05 compared to pLVX.
doi:10.1371/journal.pone.0027978.g004
Table 1. Tumorigenicity in SCID mice of NNK-transformed
clones of BEP2D cell lines isolated from soft agar.*
Cell line
Total number
of clones
injected
Number
of tumors
%o f
tumorigenic
clones
P value
(compared
to pLVX)
pLVX 18 4 28
S442 22 15 69 0.012
N442 20 2 10 0.4
*Each clone was introduced via a separate injection, as detailed in Methods.
Tumorigenicity of S442 and N442 clones was compared to that of the BEP2D
cells containing empty pLVX vector in two-tailed Fishers exact test with 95%
confidence interval.
doi:10.1371/journal.pone.0027978.t001
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phrenia [33], respectively, and that of the a1 and e subunits of the
muscle-type nAChR—with congenital myasthenic syndromes
[34,35,36]. Indeed, the presence of non-functional a1 nAChR
resulting from RNA splicing was found in muscle cells [37].
Therefore, we hypothesize that expression of different isoforms of
a9 nAChR protein affects cell cycle regulation in response to the
endogenous ligand acetylcholine.
In conclusion, we demonstrated that different variants of the
human a9 nAChR subunit protein differentially affect prolifera-
tion and neoplastic transformation of bronchial cells. Elucidation
of the mechanisms, by which individual genetic variations in
CHRNA9 affecting its expression, protein structure, and RNA
splicing influence predisposition to lung cancer may lead to the
development of personalized approaches to cancer prevention and
treatment.
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